Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

14.04.2025

1 Arch Virol
1 Biochem Biophys Res Commun
1 BMC Pediatr
1 Drug Saf
2 Epidemiol Infect
1 J Clin Microbiol
1 J Gen Virol
2 J Immunol
3 J Infect
2 J Infect Dis
2 J Virol
1 PLoS Biol
15 PLoS One
1 Proc Natl Acad Sci U S A
13 Vaccine


    Arch Virol

  1. HUANG Z, Zhang R, Yao D, Fu H, et al
    Avian influenza A(H5N6) virus detected during live-poultry market surveillance linked to a human infection in Changsha, China, from 2020 to 2023.
    Arch Virol. 2025;170:96.
    >> Share


    Biochem Biophys Res Commun

  2. ZABRODSKAYA YA, Gavrilova NV, Elpaeva EA, Lozhkov AA, et al
    Corrigendum to "mRNA encoding antibodies against hemagglutinin and nucleoprotein prevents influenza virus infection in vitro" [Biochem. Biophys. Res. Commun. 738 (2024) 150945].
    Biochem Biophys Res Commun. 2025 Apr 9:151783. doi: 10.1016/j.bbrc.2025.151783.
    >> Share


    BMC Pediatr

  3. VIANA J, Santos JV, Pinto A, Santos A, et al
    Avoidable visits to the paediatric emergency department: associated factors and lessons learned from the pandemic.
    BMC Pediatr. 2025;25:279.
    >> Share


    Drug Saf

  4. HAMZAOUI H, Shaum A, Cherkaoui I, Moussa LA, et al
    Assessment of Pharmacovigilance Across University Hospitals in Morocco.
    Drug Saf. 2025;48:527-539.
    >> Share


    Epidemiol Infect

  5. SUOMENRINNE-NORDVIK A, Leino T, Shubin M, Auranen K, et al
    Quantifying the direct and indirect components of COVID-19 vaccine effectiveness during the Delta variant era.
    Epidemiol Infect. 2025;153:e59.
    >> Share

  6. WITTEVEEN-FREIDL G, Lauenborg Moller K, Voldstedlund M, Gubbels S, et al
    Data for action - description of the automated COVID-19 surveillance system in Denmark and lessons learnt, January 2020 to June 2024.
    Epidemiol Infect. 2025;153:e58.
    >> Share


    J Clin Microbiol

  7. HEIMSCH KC, Stanoeva KR, Mogling R, Kraus A, et al
    External quality assessment of molecular detection and variant typing of SARS-CoV-2 in European expert laboratories in 2023.
    J Clin Microbiol. 2025;63:e0153824.
    >> Share


    J Gen Virol

  8. SANCHEZ-MARTINEZ A, Moore T, Freitas TS, Benzaken TR, et al
    Recent advances in the prevention and treatment of respiratory syncytial virus disease.
    J Gen Virol. 2025;106.
    >> Share


    J Immunol

  9. HATIPOGLU I, Ainsua-Enrich E, Kadel S, Turner S, et al
    IRF4-regulated transcriptional and functional heterogeneity of lung-resident CD11b+ cDC2 subsets during influenza virus infection.
    J Immunol. 2025 Apr 10:vkaf060. doi: 10.1093.
    >> Share

  10. DINANT S, Castille J, Deloizy C, Bruder E, et al
    The prion-family protein Doppel exerts a protective role during influenza virus infection.
    J Immunol. 2025 Apr 9:vkaf031. doi: 10.1093.
    >> Share


    J Infect

  11. JIN R, Qin T, Li P, Yuan J, et al
    Increased Circulation of Adenovirus in China During 2023-2024: Association with an Increased Prevalence of Species B and School-Associated Transmission.
    J Infect. 2025 Mar 21:106475. doi: 10.1016/j.jinf.2025.106475.
    >> Share

  12. PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al
    Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
    J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473.
    >> Share

  13. WADIA U, Moore HC, Richmond PC, Levy A, et al
    Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024.
    J Infect. 2025;90:106466.
    >> Share


    J Infect Dis

  14. YAMAMOTO S, Mizoue T, Ujiie M, Horii K, et al
    Low levels of post-vaccination hemagglutination inhibition antibodies and their correlation with influenza protection among healthcare workers during the 2024/2025 A/H1N1 outbreak in Japan.
    J Infect Dis. 2025 Apr 10:jiaf183. doi: 10.1093.
    >> Share

  15. LEWIS NM, Harker EJ, Cleary S, Zhu Y, et al
    Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024.
    J Infect Dis. 2025 Apr 8:jiaf185. doi: 10.1093.
    >> Share


    J Virol

  16. XU S, Liu Y, Luo C, Zhou M, et al
    Identification and characterization of a broadly neutralizing and protective nanobody against the HA1 domain of H5 avian influenza virus hemagglutinin.
    J Virol. 2025 Apr 7:e0209024. doi: 10.1128/jvi.02090.
    >> Share

  17. ADU OF, Sempere Borau M, Fruh SP, Karakus U, et al
    Cell binding, uptake, and infection of influenza A virus using recombinant antibody-based receptors.
    J Virol. 2025 Apr 10:e0227524. doi: 10.1128/jvi.02275.
    >> Share


    PLoS Biol

  18. GILBERT SC
    Priorities for rapid and cost-effective vaccines to improve outbreak responses.
    PLoS Biol. 2025;23:e3003114.
    >> Share


    PLoS One

  19. BENAVIDES FFW, Veldhuis Kroeze EJB, Leijten L, Schmitz KS, et al
    Neuroinvasive and neurovirulent potential of SARS-CoV-2 in the acute and post-acute phase of intranasally inoculated ferrets.
    PLoS One. 2025;20:e0311449.
    >> Share

  20. KAMO M, Murakami M, Naito W, Yasutaka T, et al
    Comparison of COVID-19 testing strategies and costs for professional sports teams: A case study of J. League clubs.
    PLoS One. 2025;20:e0310939.
    >> Share

  21. USTUNDAG MG, Beyhun NE, Topbas M, Turhan S, et al
    Direct medical cost of adult Covid-19 inpatients and its determinants at a university hospital.
    PLoS One. 2025;20:e0319762.
    >> Share

  22. YEHIA AC, Moreira J, Premaor MO
    Burnout syndrome in resident physicians: A study after the third COVID-19 wave in two tertiary hospitals of southeastern Brazil.
    PLoS One. 2025;20:e0321443.
    >> Share

  23. GABRIELA BAYOLO S, Miraine Davila F, Gayraud G
    Test allocation based on risk of infection from first and second order contact tracing.
    PLoS One. 2025;20:e0320291.
    >> Share

  24. BOZIC A, Podgornik R
    Increased preference for lysine over arginine in spike proteins of SARS-CoV-2 BA.2.86 variant and its daughter lineages.
    PLoS One. 2025;20:e0320891.
    >> Share

  25. LI F, Tong M, Guan S
    Changes in the network structure of energy markets and financial markets under the different shocks of the Russia-Ukraine conflict and COVID-19.
    PLoS One. 2025;20:e0318291.
    >> Share

  26. HERBERHOLZ C, Saichol P, Damrongplasit K
    Health insurance type, healthcare utilization and out-of-pocket expenditure in the face of COVID-19: Evidence from Thai national survey data.
    PLoS One. 2025;20:e0321468.
    >> Share

  27. QUIROS-RAMIREZ MA, Feineisen A, Streuber S, Reips UD, et al
    Virtual Reality experiments in the field.
    PLoS One. 2025;20:e0318688.
    >> Share

  28. ADEWOPO J, Andree BPJ, Peter H, Solano-Hermosilla G, et al
    AI-imputed and crowdsourced price data show strong agreement with traditional price surveys in data-scarce environments.
    PLoS One. 2025;20:e0320720.
    >> Share

  29. ASTETE CORNEJO J, Cruz-Ausejo L, Cainamarks Alejandro J, Burgos-Flores MA, et al
    Barriers and limitations to the development of a telemental health service for workers in Peru- A user-centered approach.
    PLoS One. 2025;20:e0321401.
    >> Share

  30. SHAW RJ, Hamilton OKL, Rhead R, Silverwood RJ, et al
    Associations between different measures of SARS-CoV-2 infection status and subsequent economic inactivity: A pooled analysis of five longitudinal surveys linked to healthcare records.
    PLoS One. 2025;20:e0321201.
    >> Share

  31. VO DH, Huynh TL, Ho CM, Vo QT, et al
    The impact of social welfare support on mental health in Vietnam.
    PLoS One. 2025;20:e0318374.
    >> Share

  32. HE T, Tu CC, Wang Z, Hao D, et al
    Potential effect of social support on perceived stress and anxiety in college students during public health crisis: Multiple interactions of gender.
    PLoS One. 2025;20:e0319799.
    >> Share

  33. J VK, Koshy JM, S D, Narreddy S, et al
    Prevalence and predictors of long COVID at 1 year in a cohort of hospitalized patients: A multicentric qualitative and quantitative study.
    PLoS One. 2025;20:e0320643.
    >> Share


    Proc Natl Acad Sci U S A

  34. LIU X, Balligand T, Le Gall C, Ploegh HL, et al
    A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses.
    Proc Natl Acad Sci U S A. 2025;122:e2424889122.
    >> Share


    Vaccine

  35. BERGSTROM F, Gunther F, Britton T
    A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
    Vaccine. 2025;52:126870.
    >> Share

  36. DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al
    Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions.
    Vaccine. 2025;52:126888.
    >> Share

  37. ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al
    Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.
    Vaccine. 2025;52:126881.
    >> Share

  38. LEBLANG D, Smith MD, Wesselbaum D
    Global perspectives on COVID-19 vaccination: Impacts on well-being and inequality.
    Vaccine. 2025;52:126906.
    >> Share

  39. DIYA O, Gayed J, Lowry FS, Ma H, et al
    A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
    Vaccine. 2025;52:126869.
    >> Share

  40. MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al
    COVID-19 vaccination integration, innovations and key populations: Results from a global survey.
    Vaccine. 2025;52:126863.
    >> Share

  41. CHU CF, Chang TH, Ho JJ
    Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.
    Vaccine. 2025;52:126830.
    >> Share

  42. PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
    Vaccine. 2025;52:126680.
    >> Share

  43. BOLU O, Alo OD, Iwara E, Longley AT, et al
    Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.
    Vaccine. 2025;52:126907.
    >> Share

  44. CHEN PL, Richardson RA, Rovito S, Yang G, et al
    Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets.
    Vaccine. 2025;53:127090.
    >> Share

  45. LLOYD PC, Acharya G, Zhao H, Shah N, et al
    Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2025;53:127069.
    >> Share

  46. ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al
    Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood.
    Vaccine. 2025;53:127047.
    >> Share

  47. ZHANG L, Xia Y, Chu L, Sundaram ME, et al
    Differences in seasonal influenza vaccine hesitancy profiles between clinicians practicing traditional Chinese medicine and modern Western medicine: A national cross-sectional survey.
    Vaccine. 2025;53:127106.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016